Information:
Fel:
ID
37246
Beskrivning
Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms; ODM derived from: https://clinicaltrials.gov/show/NCT02403505
Länk
https://clinicaltrials.gov/show/NCT02403505
Nyckelord
Versioner (1)
- 2019-07-11 2019-07-11 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
11 juli 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Stage, Prostate Cancer NCT02403505
Eligibility Stage, Prostate Cancer NCT02403505
- StudyEvent: Eligibility
Similar models
Eligibility Stage, Prostate Cancer NCT02403505
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Prostate carcinoma
Item
clinical diagnosis of prostate cancer
boolean
C0600139 (UMLS CUI [1])
Prostate carcinoma Biopsy
Item
clinical biopsy diagnosis of prostate cancer
boolean
C0600139 (UMLS CUI [1,1])
C0005558 (UMLS CUI [1,2])
C0005558 (UMLS CUI [1,2])
Suitable Local Therapy Surgery
Item
suitable for local therapy with surgery
boolean
C3900053 (UMLS CUI [1,1])
C1517925 (UMLS CUI [1,2])
C0543467 (UMLS CUI [1,3])
C1517925 (UMLS CUI [1,2])
C0543467 (UMLS CUI [1,3])
Randomization | Double-Blind Method
Item
random and double blind
boolean
C0034656 (UMLS CUI [1])
C0013072 (UMLS CUI [2])
C0013072 (UMLS CUI [2])
Measurable Disease
Item
measurable disease
boolean
C1513041 (UMLS CUI [1])
Organ function
Item
adequate organ functions
boolean
C0678852 (UMLS CUI [1])
Performance status Adequate
Item
adequate performance status
boolean
C1518965 (UMLS CUI [1,1])
C0205411 (UMLS CUI [1,2])
C0205411 (UMLS CUI [1,2])
Age
Item
age 22 years old and over
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
sign an informed consent form
boolean
C0021430 (UMLS CUI [1])
Cancer treatment Other | Cancer treatment Discontinue Unsuccessful
Item
treatment with other anti-cancer therapies and cannot be stopped currently
boolean
C0920425 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0920425 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C1272705 (UMLS CUI [2,3])
C0205394 (UMLS CUI [1,2])
C0920425 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C1272705 (UMLS CUI [2,3])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
Breast Feeding
Item
breast-feeding
boolean
C0006147 (UMLS CUI [1])
Comorbidity Serious | Communicable Diseases
Item
the patients with other serious inter-current illness or infectious diseases
boolean
C0009488 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2])
C0205404 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2])
Cancer Other Quantity
Item
have more than one different kind of cancer in the same time
boolean
C1707251 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
Drug Allergy
Item
allergy to drugs
boolean
C0013182 (UMLS CUI [1])
Bleeding tendency Serious
Item
serious bleed tendency
boolean
C1458140 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,2])
Investigational New Drug At risk Serious | Investigational New Drug Adverse event Serious
Item
serious risks or serious adverse events of the drug product
boolean
C0013230 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2,1])
C0877248 (UMLS CUI [2,2])
C0205404 (UMLS CUI [2,3])
C1444641 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2,1])
C0877248 (UMLS CUI [2,2])
C0205404 (UMLS CUI [2,3])
Prohibition Pharmaceutical Preparation
Item
the prohibition of the drug product
boolean
C0683610 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,2])
Prohibition Pharmaceutical Preparation Label Current
Item
up to most current label
boolean
C0683610 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C1705425 (UMLS CUI [1,3])
C0521116 (UMLS CUI [1,4])
C0013227 (UMLS CUI [1,2])
C1705425 (UMLS CUI [1,3])
C0521116 (UMLS CUI [1,4])